title: Body iron delocalization: the serious drawback in iron disorders in both developing and developed countries.
abstract: Over 2 billion people in both developing as well as developed countries - over 30% of the world's population - are anaemic. With the classical preconception that oral iron administration or the intake of foods rich in iron increase haemoglobin concentration and reduce  the prevalence of anaemia, specific programs have been designed, but iron supplementations have been less effective than expected. Of note, this hazardous simplification on iron status neglects its distribution in the body. The correct balance of iron, defined iron homeostasis, involves a  physiological ratio of iron between tissues/secretions and blood, thus avoiding its delocalization as iron accumulation in tissues/secretions and iron deficiency in blood. Changes in iron status can affect the inflammatory response in multiple ways, particularly in the context of infection,  an idea that is worth remembering when considering the value of iron supplementation in areas of the world where infections are highly prevalent. The enhanced availability of free iron can increase susceptibility and severity of microbial and parasitic infections. The discovery of the hepcidin-ferroportin  (Fpn) complex, which greatly clarified the enigmatic mechanism that supervises the iron homeostasis, should prompt to a critical review on iron supplementation, ineffective on the expression of the most important proteins of iron metabolism. Therefore, it is imperative to consider new safe  and efficient therapeutic interventions to cure iron deficiency (ID) and ID anaemia (IDA) associated or not to the inflammation. In this respect, lactoferrin (Lf) is emerging as an important regulator of both iron and inflammatory homeostasis. Oral administration of Lf in subjects suffering  of ID and IDA is safe and effective in significantly increasing haematological parameters and contemporary decreasing serum IL-6 levels, thus restoring iron localization through the direct or indirect modulation of hepcidin and ferroportin synthesis. Of note, the nuclear localization of Lf  suggests that this molecule may be involved in the transcriptional regulation of some genes of host inflammatory response. We recently also reported that combined administration of oral and intravaginal Lf on ID and IDA pregnant women with preterm delivery threat, significantly increased  haematological parameters, reduced IL-6 levels in both serum and cervicovaginal fluid, cervicovaginal prostaglandin PGF2α, and suppressed uterine contractility. Moreover, Lf combined administration blocked further the shortening of cervical length and the increase of foetal fibronectin,  thus prolonging the length of pregnancy until the 37th-38th week of gestation. These new Lf functions effective in curing ID and IDA through the restoring of iron and inflammatory homeostasis and in preventing preterm delivery, could have a great relevance in developing countries,  where ID and IDA and inflammation-associated anaemia represent the major risk factors of preterm delivery and maternal and neonatal death.
authors.affiliation: Department of Woman Health and Territorial Medicine, Sapienza University of Rome, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Paesano
authors.forename: T
authors.initials: T
authors.lastname: Natalizi
authors.forename: F
authors.initials: F
authors.lastname: Berlutti
authors.forename: P
authors.initials: P
authors.lastname: Valenti
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000453:epidemiology*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D019049:Developed Countries; D003906:Developing Countries; D006706:Homeostasis; D006801:Humans; D007501:Iron / Q000378:metabolism*; D000090463:Iron Deficiencies; D007781:Lactoferrin / Q000627:therapeutic use*; D008659:Metabolic Diseases / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D007501:Iron; D007781:Lactoferrin